Product Overview

Innovative Therapies for Bacterial & Viral Infections

Aridis Pipeline

 

Aridis is discovering and developing highly differentiated drug candidates to prevent and treat life-threatening infectious diseases that overcome the threat of AMR and global viral outbreaks, with both therapeutic monoclonal antibodies and novel anti-infectives designed to complement the current standards of care.

 

Fully human monoclonal antibodies (mAb) directed against infectious disease targets is a growing area of drug development interests. Anti-infective mAbs is a new class of anti-infective that has the potential to be standard of care treatments due to their strong safety profile in humans, remarkably long plasma half-life and low risk of drug resistance.

Aridis has developed a suite of human mAbs as anti-infective drugs targeting key human pathogens, including S. aureus (MRSA & MSSA), P. aeruginosa, A. baumannii bacteria and respiratory syncytial virus. Complementing these mAbs is a broad spectrum anti-infective candidate based on the unique iron analog properties of gallium (Panaecin®).